Biopharma giants are strengthening pipelines through collaboration and investment. Novartis agreed to a $60 million upfront deal with Matchpoint Therapeutics to develop oral covalent inhibitors targeting transcription factors linked to inflammatory diseases. Lilly inked a deal valued up to $856 million with Gate Bioscience to develop molecular gate therapeutics aimed at eliminating difficult-to-drug proteins, bolstering their innovative therapy portfolio. Additional biopharma investment rounds, such as TCG Labs Soleil’s $400 million venture for single-asset biotechs and Bioanalytical CRO Dash Bio’s $11 million funding, showcase robust capital flow into R&D and platform expansions. These collaborations and financings signal a continuing appetite for novel modalities in addressing unmet therapeutic needs.